• 1
    Banham L., Gilbody S. Smoking cessation in severe mental illness: what works? Addiction 2010; 105: 117689.
  • 2
    De Leon J., Diaz F. J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76: 13557.
  • 3
    Williams J. M., Ziedonis D. M., Abanyie F., Steinberga M. L., Foulds J., Benowitz N. L. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr Res 2005; 79: 32335.
  • 4
    Strand J.-E., Nybäck H. B. Tobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls. Eur Psychiatry 2005; 20: 504.
  • 5
    Weinberger A. H., Reutenauer E. L., Allen T. M., Termine A., Vessicchio J. C., Sacco K. A. et al. Reliability of the Fagerstrom Test for Nicotine dependence, Minnesota Nicotine Withdrawal Scale, and Tiffany Questionnaire for smoking urges in smokers with and without schizophrenia. Drug Alcohol Depend 2007; 86: 27882.
  • 6
    Rabin R. A., Sacco K. A., George T. P. Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status. Schizophr Res 2009; 114: 917.
  • 7
    Tidey J. W., Rohsenow D. J., Kaplan G. B., Swift R. M. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend 2005; 80: 25965.
  • 8
    Barr A. M., Procyshyn R. M., Hui P., Johnson J. L., Honer W. G. Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr Res 2008; 100: 25260.
  • 9
    Prochaska J. J., Leek D. N., Hall S. E., Hall S. M. Cognitive interviews for measurement evaluation of the Fagerström Test for Nicotine Dependence (FTND) in smokers with schizophrenia spectrum disorders. Addict Behav 2007; 32: 793802.
  • 10
    Colton C. W., Manderscheid R. W. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 3: A42.
  • 11
    Miller B. J., Paschall C. B. III, Svendsen D. P. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 2006; 57: 14827.
  • 12
    Addington J. Group treatment for smoking cessation among persons with schizophrenia. Psychiatr Serv 1998; 49: 9258.
  • 13
    Fagerström K., Aubin H. J. Management of smoking cessation in patients with psychiatric disorders. Curr Med Res Opin 2009; 25: 51118.
  • 14
    Hall S. M., Prochaska J. J. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol 2009; 5: 40931.
  • 15
    Chapman S., MacKenzie R. The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Med 2010; 7: e1000216.
  • 16
    Department of Health. 2010; (accessed 26 April 2010).
  • 17
    Stapleton J. A., Watson L., Spirling L. I., Smith R., Milbrandt A., Ratcliffe M. et al. Varenicline in the routine treatment of tobacco dependence: a pre–post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008; 103: 14654.
  • 18
    Gunnell D., Irvine D., Wise L., Davies C., Martin R. M. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805; doi:10.1136/bmj.b3805.